Abstract: Liquid fabric care compositions that includes vinegar and/or acetic acid; fragrance materials; and water; where the fragrance materials are characterized by a log P of less than about 2.5; and where the fabric care composition is characterized by an acidic pH. Related processes of making and using such compositions.

Abstract: Cleaning compositions and processes for making and using same. In some examples, the cleaning composition can include about 0.02 wt % to about 26 wt % of a neutralized tall oil fatty acids; about 0.01 wt % to about 9 wt % of a solvent; and about 65 wt % to about 99.97 wt % of water, where all weight percent values are based on a combined weight of the neutralized tall oil fatty acids, the solvent, and the water.

Abstract: Laundry additive compositions that include a metal sequestration agent and that may be characterized by an acidic pH. Related methods of treating a fabric, for example with a wash liquor and a rinse liquor, with such compositions and/or agents. Uses of such laundry additive compositions.

Abstract: A simplified method for removing foreign matters formed on a substrate in a semiconductor device manufacturing process; and a composition for forming a coating film for foreign matter removal use, which can be used in the method. A coating film is formed on a semiconductor substrate using a composition preferably containing a polyamic acid produced from (a) a tetracarboxylic dianhydride compound and (b) a diamine compound having at least one carboxyl group or a polyamic acid produced from (a) a tetracarboxylic dianhydride compound, (b) a diamine compound having at least one carboxyl group and (c) a diamine compound, and then foreign matters occurring on the coating film are removed together with the coating film by the treatment with a developing solution.

Abstract: The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.

Abstract: A beverage maker may include a fermentation tank having a space to make a beverage therein; an ingredient supplier having a space to contain at least some of ingredients for making the beverage; a water tank configured to contain water to make the beverage; an output interface including at least one of a display or a speaker; and a controller configured to control a beverage making preparation operation and a beverage making operation for making the beverage. When the beverage making preparation operation is completed, the controller may be configured to output a request for removal of a residual ingredient of the ingredient supplier and residual water of the water tank through the output interface.

Abstract: A beverage maker may include a fermenter having a space therein to make a beverage; a fluid tank configured to contain fluid; a fluid supply pump connected with the fluid tank; a flow rate detection sensor disposed in a channel connected with the fluid supply pump to detect a flow velocity or a flow rate of fluid which is discharged through the channel by the fluid supply pump; and a controller configured to perform a plurality of operations related to making of a beverage or cleaning of an inside of the beverage maker. The controller may be configured to when an operation requiring a supply of fluid is ongoing from among the plurality of operations, turn on the fluid supply pump to discharge fluid contained in the fluid tank; detect a lack of fluid in the fluid tank based on a first flow velocity or a first flow rate detected by the flow rate detection sensor; and generate a fluid replenishment request for the fluid tank based on a result of detecting.

Abstract: A beverage maker may include a fermentation tank defining a space to make a beverage therein; a display; an input interface configured to receive recipe information of a beverage to be made in the fermentation tank; and a controller configured to set a making environment of the beverage based on the received recipe information, and to control a making function of the beverage based on the set making environment. The controller may be configured to receive a recipe check request through the input interface, and to display the recipe information through the display based on the received recipe check request.

Abstract: A system and method are provided to produce a beverage concentrate such as a beer extract. A forward osmosis (FO) filtration technique removes pure water from a conventional brewed beer; accordingly, the beer extract can be produced without distillation or other alteration steps that may negatively impact of flavor and aroma components of the beer. A draw solution is used to provide a differential osmotic pressure through a FO filtration device. The diluted draw solution is recycled by reverse osmosis, distillation, and combinations thereof.

Abstract: A novel Self-Locking Optoelectronic Tweezers (SLOT) for single microparticle manipulation across a large area is provided. DEP forces generated from ring-shape lateral phototransistors are utilized for locking single microparticles or cells in the dark state. The locked microparticles or cells can be selectively released by optically deactivating these locking sites.

Abstract: The invention discloses a bioreactor 10 for cell culture and expansion, comprising a bioreactor chamber 17, a filter 13 disposed within the chamber 17 and at least one tether 14 loosely tethering the filter to the bioreactor chamber. In an embodiment, the tether(s) allow the filter 13 to move from side to side and/or up and down within the chamber 17, preferably without touching an inner surface of the bioreactor chamber 17. Alternatives show, two, three or four tethers, but one or more tethers can be used.

Abstract: Apparatus and methods for delivering biological samples to an ICP source of a mass cytometer are disclosed. Biological material is disposed on a plurality of discrete sites on a carrier. The plurality of discrete sites are configured to retain biological material and to release the biological material upon application of energy. The carrier is positioned in proximity to a gas conduit and upon release from the discrete sites, the biological material becomes entrained in a gas flow, which delivers discrete portions of biological material through the conduit to the ICP source for analysis by mass cytometry. The apparatus and methods can provide a continuous stream of discrete portions of biological material to a mass cytometer or mass spectrometer.

Abstract: A 3D-printed in vitro model biological microenvironment in examples discussed below may have one or more of the following features: (a) a gel matrix 3D-printed scaffold, wherein the gel matrix comprises a chemical composition configured to culture a first type of live cells, (b) a target chemical disposed at one or more locations within the gel matrix, the target chemical forming a chemical depot from which a chemical gradient is created within the gel matrix, (c) a conduit disposed within the gel matrix and defining a lumen comprising a second type of live cells, wherein the conduit is configured to enable at least some of the first type of live cells to migrate through the conduit and facilitate flow of at least: some of the live cells to an outlet of the conduit, or enable introduction of at least one of other cells, Achemical mediators, or drugs into the 3D-printed microenvironment.

Abstract: Compositions and methods are provided for modulating the growth, development and repair of bone, cartilage or other connective tissue. Devices and stimulus waveforms are provided to differentially modulate the behavior of osteoblasts, chondrocytes and other connective tissue cells to promote proliferation, differentiation, matrix formation or mineralization for in vitro or in vivo applications. Continuous-mode and pulse-burst-mode stimulation of cells with charge-balanced signals may be used. Bone, cartilage and other connective tissue growth is stimulated in part by nitric oxide release through electrical stimulation and may be modulated through co-administration of NO donors and NO synthase inhibitors. Bone, cartilage and other connective tissue growth is stimulated in part by release of BMP-2 and BMP-7 in response to electrical stimulation to promote differentiation of cells.

Abstract: At least one tool removably mountable on a cell incubator mandrel or a cell incubator having at least one mandrel having an end portion, the at least one mandrel mounted on a movable transport for moving the at least one mandrel and at the least one tool removably mountable on the end portion of the at least one mandrel. The at least one tool is preferably electrically powered and controllable by signals applied to the at least one tool to perform at least one operation with respect to the incubation of cells.

Abstract: An egg sealing unit for an automated biological sample collection system and method of use. The egg sealing unit seals the section of egg from which the shell has been removed. The egg sealing unit includes a sampler, an applicator and an imaging adaptor providing an optical conduit between the surface of an egg and the CAM. The applicator is configured to deliver exogenous material to the CAM, the sampler is configured to collect samples from the CAM and the imaging adaptor allows the CAM to be monitored.

Abstract: Methods, apparatus, systems and articles of manufacture are disclosed herein to implement flexible bioreactor control systems. An example apparatus disclosed herein includes a processor coupled to a memory, the processor programmed to determine whether the map value included in the process task object is a valid map value, the process task object to correspond to a task executed by a bioreactor, a control device or a measurement device of the bioreactor control system configuration, in response to determining the map value is a valid map value, decode the map value to identify the source location of a first input of the process task object, pull a value from the source location to update the input value of the process task object, and facilitate execution of the process task with the input value.

Abstract: The present invention relates to food-grade bacteria and methods for removing toxic compounds, including lead, cadmium, mercury, arsenic and pesticides, from contaminated environments or substances.

Abstract: The present invention provides a method for swiftly producing a layered cell sheet that is non-invasively obtained and is utilizable for transplantation, etc., the method including (1) a step of applying a centrifugal force to a first cell sheet on a temperature-responsive culture surface for a predetermined time in a temperature range from a lower critical solution temperature of the temperature-responsive culture surface to 45° C., (2) a step of further placing a second cell sheet on the first cell sheet, and (3) a step of applying a centrifugal force to the first cell sheet and the second cell sheet on the temperature-responsive culture surface for a predetermined time in the temperature range from the lower critical solution temperature to 45° C.; and also provides a layered cell sheet obtained by the method.

Abstract: A composition comprising a plurality of cell aggregates for use in the production of engineered organotypic tissue by organ printing. A method of making a plurality of cell aggregates comprises centrifuging a cell suspension to form a pellet, extruding the pellet through an orifice, and cutting the extruded pellet into pieces. Apparatus for making cell aggregates comprises an extrusion system and a cutting system. In a method of organ printing, a plurality of cell aggregates are embedded in a polymeric or gel matrix and allowed to fuse to form a desired three-dimensional tissue structure. An intermediate product comprises at least one layer of matrix and a plurality of cell aggregates embedded therein in a predetermined pattern. Modeling methods predict the structural evolution of fusing cell aggregates for combinations of cell type, matrix, and embedding patterns to enable selection of organ printing processes parameters for use in producing an engineered tissue having a desired three-dimensional structure.

Abstract: Structures and methods for tissue engineering include a multicellular body including a plurality of living cells. A plurality of multicellular bodies can be arranged in a pattern and allowed to fuse to form an engineered tissue. The arrangement can include filler bodies including a biocompatible material that resists migration and ingrowth of cells from the multicellular bodies and that is resistant to adherence of cells to it. Three-dimensional constructs can be assembled by printing or otherwise stacking the multicellular bodies and filler bodies such that there is direct contact between adjoining multicellular bodies, suitably along a contact area that has a substantial length. The direct contact between the multicellular bodies promotes efficient and reliable fusion. The increased contact area between adjoining multicellular bodies also promotes efficient and reliable fusion.

Abstract: The invention is directed to a method for producing an edible composition, comprising incubating a three-dimensional porous scaffold and a plurality of cell types comprising: myoblasts or progenitor cells thereof, at least one type of extracellular (ECM)-secreting cell and endothelial cells or progenitor cells thereof, and inducing myoblasts differentiation into myotubes.

Abstract: Disclosed herein are compositions and methods for treating, ameliorating or preventing a retinal disease or condition; improving a photopic (day light) vision; for improving correcting visual acuity, improving macular function, improving a visual field, or improving scotopic (night) vision by administration of retinal progenitor cells.

Abstract: This invention relates to a novel approach for the generation of human induced neural border stem cells (iNBSCs) by the direct conversion of somatic cells (peripheral blood, skin biopsies) and to novel uses of such cells, including the differentiation of these stem cells into cell types of the CNS and the neural crest lineages, and the uses of such cells.

Abstract: The invention provides a method for the expansion of anti-tumor T-cells, comprising the steps of: a) providing a phagocytosable particle, having one or more tumor neoantigenic constructs tightly associated thereto, wherein the tumor neoantigenic construct comprises an amino-acid sequence comprising at least one mutated amino acid known or suspected to be associated with a cancer in a subject, or a mutated or non-mutated amino-acid sequence known or suspected to be expressed in a cancer cell in the subject; b) providing a viable antigen-presenting cell; c) contacting the particle with the antigen-presenting cell in vitro under conditions allowing phagocytosis of the particle by the antigen-presenting cell; d) providing a T-cell sample comprising viable T-cells from the subject; e) contacting the T-cell sample with the antigen-presenting cell contacted with the particle in vitrounder conditions allowing specific activation of anti-tumor T-cells in response to antigen presented by the antigen-presenting cell.

Abstract: The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.

Abstract: Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer, such as PTK7+ malignancies.

Abstract: A method for expanding a population of ?? T-cells is provided in which isolated activated Peripheral Blood Mononuclear Cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-?) under conditions in which the production of effector ?? T-cells having therapeutic activity against malignant disease is favored. The use of TGF-? in the production of effector cells in particular V?9V?2 T-cells is also described and claimed.

Abstract: A method to expand hematopoietic stem and progenitor cells (HSPC) wherein the method comprises obtaining an isolated population of HSPC the culturing the isolated population of HSPC in the presence of a histone deacetylase inhibitor (HDAC inhibitor), to form a cultured population, then adding an aminothiol compound to the cultured population.

Abstract: The present invention relates to a method for the isolation of subpopulations of cardiac progenitor cells from a heart tissue sample, the population thus obtained and the related uses in the medical field for the cell therapy or cardiac cell and/or tissue transplantation field.

Abstract: The present invention provides methods for isolating human cardiac ventricular progenitor cells (HVPs), wherein cultures of day 5-7 cardiac progenitor cells are negatively selected for one or more first markers expressed on human pluripotent stem cells, such as TRA-1-60, to thereby isolate HVPs. The methods can further include positive selection for expression of a second marker selected from the group consisting of JAG1, FZD4, LIFR, FGFR3 and TNFSF9. Large populations, including clonal populations, of isolated HVPs that are first marker negative/second marker positive are also provided. Methods of in vivo use of the HVPs for cardiac repair or to improve cardiac function are also provided. Methods of using the HVPs for cardiac toxicity screening of test compounds are also provided.

Abstract: The invention is directed to a method for the preparation of a multiring engineered heart tissue construct suitable for use in cardiac tissue augmentation and/or replacement therapy. The invention further refers to multiring EHT constructs which comprise at least two force-generating engineered heart tissue rings fused with each other and a device for preparing the same. Finally, the invention relates to force-generating engineered heart tissue rings derived from human cells and their use in drug screening and target validation assays.

Abstract: Systems and methods for producing cell cultured food products. The cultured food products include sushi-grade fish meat, fish surimi, foie gras, and other food types. Various cell types are utilized to produce the food products and can include muscle, fat, and/or liver cells. The cultured food products are grown in pathogen-free culture conditions without exposure to toxins and other undesirable chemicals.

Abstract: The present invention relates to a method for determining the biological activity or therapeutic efficacy of cultured mesenchymal lineage precursor cells or stem cells based on their released TGF-9 levels in culture. The present invention also relates to isolated populations of mesenchymal lineage precursor cells or stem cells selected based on the level of TGF-9 levels released by such cells in culture. The present invention further relates to treatment of a subject suffering from a degenerative disc disease by administering such selected cell populations.

Abstract: A method for revitalizing mesenchymal stem cells (MSC) maintained in culture by transducing the MSC with vectors encoding a specific gene combination, as well as methods of use of MSC so revitalized in co-culturing hematopoietic stem cells.

Abstract: Provided herein are enhanced systems for potentiating cell-mediated oncolytic viral therapy. Also provided are modified viruses for such systems, and methods of treatment of cancers by administering such systems.

Abstract: Disclosed herein are methods for manufacturing transdifferentiated populations of non-pancreatic human insulin producing cells, and methods for enriching populations of non-pancreatic ?-cells for cells comprising an enriched capacity for transcription factor-induced transdifferentiation into a pancreatic ?-cell phenotype and function.

Abstract: The present invention relates to a method of culturing a pancreatic progenitor cell. The method comprises contacting the cell with epidermal growth factor (EGF), retinoic acid (RA) and an inhibitor of transforming growth factor-? (TGF-?) and 3T3-J2 feeder cells. A cell produced by the method of the invention and a kit when used in the method are also provided.

Abstract: This disclosure relates a composition and method for promoting the reprogramming of somatic cells to induced pluripotent stem cells, the composition comprising gelatin and laminin. The disclosure further relates to a method of preparing somatic cells for producing induced pluripotent stem cells and a method for producing induced pluripotent stem cells, and thus provides method useful for the production of expanded somatic cells and induced pluripotent stem cells for use in research and therapy.

Abstract: An antibody that binds a glycosylated protein is disclosed, wherein the glycosylation comprises the glycan motif Fuc?1-2Gal?1-3GlcNAc?1-3Gal?1 or Fuc?1-2Gal?1-3GlcNAc. Antibodies that are cytotoxic against undifferentiated pluripotent cells are also disclosed.

Abstract: The present disclosure relates to a novel murine parvovirus, sequences encoded thereby, and applications therefor. In one embodiment the disclosure provides a method for detecting the presence of a parvovirus in a sample, comprising detecting one or more nucleic acids or polypeptides derived from the parvovirus, or antibodies against the parvovirus, in the sample. Also provided are vectors and host cells comprising sequences encoded by the parvovirus and related sequences. Also provided are animal models of kidney disease associated with infection by the parvovirus.

Abstract: A Bradyrhizobium monooxygenase, a gene for encoding the monooxygenase, a recombinant expression vector comprising the gene and a recombinant transformant, a method of preparing the monooxygenase by the recombinant expression transformant, and a method of preparing an optically pure chiral sulfoxide by the monooxygenase, in particular to a method of preparing prazole drugs by means of catalyzing the asymmetric oxidation of thioether, a prazole precursor. As compared with other methods of preparing an optically pure sulfoxide, the product produced by the monooxygenase of the present invention as a catalyst has high optical purity, avoids the generation of the byproduct sulfone, and has advantages of mild reaction conditions, simple and convenient operations, easy amplification, etc.

Abstract: A DNA plasmid useful for diagnostic and therapeutic gene therapy is disclosed. Improvements to gene therapy methods known in the art are provided to ensure cancer-targeting, high efficacy, and long durability of expression. The DNA plasmid is combined with compositions of polymeric nanoparticles for non-viral gene therapy to treat cancer, including hepatocellular carcinoma and prostate cancer.

Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises any one amino acid sequence of SEQ ID NO:1 to SEQ ID NO:161, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide that has at least one amino acid sequence of SEQ ID NO:1 to SEQ ID NO:161 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.

Abstract: The present invention relates to the field of genetic engineering, particularly to phytase variant YeAPPA having improved pepsin resistance and acid resistance, and increased catalytic efficiency, by substituting Leucine at the 162th site of the sequence set forth in SEQ ID NO.1 with glycine or proline or substituting glutamic acid at the 230th site of the sequence set forth in SEQ ID NO.1 with glycine, proline or arginine, in the benefit of the development of economical feed enzyme industry.

Abstract: Provided are Shp2- and Spleen tyrosine kinase (Syk)-integrated sensing and actuating protein (iSNAP) (Shp2- and Syk-iSNAP) chimeric proteins comprising: a bi-phosphorylatable peptide, optionally a bisphosphoryl tyrosine-based activation (BTAM) motif; a Fluorescent Protein (FP) Förster Resonance Energy Transfer (FRET) (or FP FRET) pair or pair of motifs; a truncated Shp2 domain comprising an N-Src Homology 2(N-SH2) domain and a C-Src Homology 2(C-SH2) domain; and, a phosphatase (PTP) domain or a kinase domain. Provided are engineered cells and methods for cancer cell or tumor eradication, or for the treatment or amelioration of a cancer, tumor or dysfunctional cell, or for promoting an anti-cancer, anti-tumor or anti-dysfunctional cell inflammatory response, including enhancing macrophage-, monocyte-, microglia-, osteoclast-, Kupffer cell- or dendritic cell-mediated antibody- or monoclonal antibody (mAb)-guided cancer or dysfunctional cell or tumor eradication, amelioration, or treatment.

Abstract: Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenomic engineering, genome targeting, and genome editing.

Abstract: The present invention provides a method for preparation of an enzyme-modified stevia sugar. The method includes the steps of adding a ?-fructosidase to a solution in which a stevia sugar raw material and sucrose are dissolved to obtain a reaction solution, adjusting the pH of the reaction solution to be 5.0-8.0, maintaining a reaction temperature at 20-45° C., and after a reaction with stirring, collecting the enzyme-modified stevia sugar. The stevia sugar raw material includes one or more of stevioside and rebaudioside A, and the ?-fructosidase is derived from Microbacterium saccharophilum or Aspergillus japonicus. The preparation method takes a short time, is efficient and convenient to operate, low in cost, high in conversion rate, green and environmentally friendly, and can be widely applied to industrial scale production. The present invention further provides an enzyme for preparation of the enzyme-modified stevia sugar and application thereof.

Abstract: A di-enzymatic chimeric endolysin includes a primary enzymatic active domain including a primary protein sequence and that cleaves a glycosidic, peptide, or amide bond; a secondary enzymatic active domain disposed at a C-terminus end of the di-enzymatic chimeric endolysin and including a secondary protein sequence that, in combination with the primary enzymatic active domain, synergistically cleaves glycosidic, peptide, or amide bonds in a peptidoglycan; a cell wall binding domain including a recognition sequence that is sequentially interposed between the primary protein sequence and the secondary protein sequence and that binds to a cell wall; and a tertiary structure such that the primary enzymatic active domain faces and opposes the secondary enzymatic active domain in the di-enzymatic chimeric endolysin for synergistic cleavage of the peptidoglycan.

Abstract: The invention relates to a process for the manufacturing and purification of recombinant enzyme products, in particular of food enzyme products and the use thereof. The invention particularly relates to a process for the processing of enzyme products from a microbial fermentation broth by methods of separation, enzymatic treatment and filtration procedures.